Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 17/20 | 0.78 |
| ▸ | CYP11B2 | P19099 | 17/20 | 0.78 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1874536 | 0.89 | CYP11B1 (0.77) | CYP11B1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL1880706 | 0.88 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL1762354 | 0.88 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL1885596 | 0.87 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL6912243 | 0.85 | CYP11B1 (0.79) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL1884173 | 0.85 | CYP11B1 (0.79) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL1883196 | 0.84 | CYP11B1 (0.78) | CYP11B1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL7978823 | 0.83 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL1875479 | 0.83 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL1884471 | 0.80 | CYP11B1 (0.78) | CYP11B1CYP11B2CYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541404-B2 | Inhibitors of the human aldosterone synthase CYP11B2 | ELEXOPHARM GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541404-B2 | Inhibitors of the human aldosterone synthase CYP11B2 | ELEXOPHARM GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541404-B2 | Inhibitors of the human aldosterone synthase CYP11B2 | ELEXOPHARM GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2280954-B1 | 6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2 | UNIV SAARLAND (DE) | 2013-03-27 | — | — | EP | disclosed |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
| WO-2009135651-A1 | 6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2 | UNIVERSITÄT SAARLANDES (DE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | HSD11B1, HSD11B2, CYP4A11 | CYP11B1 6/4885CYP11B2 4/4885CYP19A1 52/4885 |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | HSD11B1, HSD11B2, CYP11B1 | CYP11B1 3/4885CYP11B2 4/4885CYP19A1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.